Log in

Mesoblast Stock Price, News & Analysis (NASDAQ:MESO)

$5.99
-0.22 (-3.54 %)
(As of 10/20/2019 04:00 PM ET)
Today's Range
$5.96
Now: $5.99
$6.10
50-Day Range
$4.83
MA: $6.15
$7.59
52-Week Range
$3.35
Now: $5.99
$8.15
Volume17,018 shs
Average Volume39,325 shs
Market Capitalization$597.38 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
CUSIPN/A
CIKN/A
Phone61-3-9639-6036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.72 million
Book Value$4.82 per share

Profitability

Net Income$-89,800,000.00
Net Margins-536.97%

Miscellaneous

Employees81
Market Cap$597.38 million
Next Earnings Date11/21/2019 (Estimated)
OptionableOptionable

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.


Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) issued its quarterly earnings data on Thursday, August, 29th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. The firm earned $1.97 million during the quarter, compared to the consensus estimate of $1.31 million. Mesoblast had a negative net margin of 536.97% and a negative return on equity of 17.66%. View Mesoblast's Earnings History.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release their next quarterly earnings announcement on Thursday, November 21st 2019. View Earnings Estimates for Mesoblast.

What price target have analysts set for MESO?

5 analysts have issued 1-year price objectives for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they expect Mesoblast's share price to reach $12.40 in the next twelve months. This suggests a possible upside of 107.0% from the stock's current price. View Analyst Price Targets for Mesoblast.

What is the consensus analysts' recommendation for Mesoblast?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast.

Has Mesoblast been receiving favorable news coverage?

News articles about MESO stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mesoblast earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Mesoblast.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $5.99.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $597.38 million and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.View Additional Information About Mesoblast.

What is Mesoblast's official website?

The official website for Mesoblast is http://www.mesoblast.com/.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (NASDAQ MESO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  329 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  531
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel